Phase 3 Trial of Nizubaglustat for Niemann-Pick Type C Disease Initiated
Azafaros B.V. has initiated Phase 3 trial to assess the safety and efficacy of oral nizubaglustat in Niemann-Pick Type C disease.
Therapeutic Area
Therapeutic area intelligence for Niemann-Pick Type C Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.